Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Deferred Revenue (2018 - 2023)

Historic Current Deferred Revenue for Revolution Medicines (RVMD) over the last 6 years, with Q1 2023 value amounting to $1.4 million.

  • Revolution Medicines' Current Deferred Revenue fell 8745.74% to $1.4 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.4 million, marking a year-over-year decrease of 8745.74%. This contributed to the annual value of $4.5 million for FY2022, which is 6391.81% down from last year.
  • Per Revolution Medicines' latest filing, its Current Deferred Revenue stood at $1.4 million for Q1 2023, which was down 8745.74% from $4.5 million recorded in Q4 2022.
  • In the past 5 years, Revolution Medicines' Current Deferred Revenue ranged from a high of $17.1 million in Q4 2019 and a low of $1.4 million during Q1 2023
  • In the last 5 years, Revolution Medicines' Current Deferred Revenue had a median value of $11.8 million in 2020 and averaged $11.0 million.
  • Per our database at Business Quant, Revolution Medicines' Current Deferred Revenue surged by 1618.09% in 2022 and then crashed by 8745.74% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' Current Deferred Revenue stood at $17.1 million in 2019, then dropped by 29.27% to $12.1 million in 2020, then increased by 2.04% to $12.4 million in 2021, then tumbled by 63.92% to $4.5 million in 2022, then plummeted by 67.84% to $1.4 million in 2023.
  • Its last three reported values are $1.4 million in Q1 2023, $4.5 million for Q4 2022, and $9.7 million during Q3 2022.